Vertaile menetelmiä
Tarkastele valitsemiasi menetelmiä rinnakkain; eroavat rivit korostetaan.
| Caco-2-soluuttimääritys× | Fysiologiapohjainen farmakokinetiikka× | |
|---|---|---|
| Tieteenala | Farmakologia | Farmakologia |
| Menetelmäperhe | Process / pipeline | Process / pipeline |
| Syntyvuosi≠ | 1989 | 1997 |
| Kehittäjä≠ | Ingrid Hidalgo | Ivan Nestorov |
| Tyyppi≠ | absorption screening | predictive modeling |
| Alkuperäislähde≠ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ | Nestorov, I. (1997). Sensitivity analysis of pharmacokinetic and pharmacodynamic systems. Journal of Pharmacokinetics and Biopharmaceutics, 25(4), 529-543. link ↗ |
| Rinnakkaisnimet≠ | Caco-2 assay, intestinal permeability, ADME screening | PBPK, PBPK modeling |
| Liittyvät | 3 | 3 |
| Tiivistelmä≠ | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. | PBPK is a mechanistic modeling framework that uses physiological parameters, tissue properties, and drug-specific attributes to predict drug concentration time profiles in the body. Developed rigorously in the 1990s by researchers including Nestorov, PBPK integrates anatomy, biochemistry, and kinetics to enable rational drug development, bridging in vitro data to clinical outcomes. |
| ScholarGateAineisto ↗ |
|
|